Trial Profile

Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Loncastuximab tesirine (Primary) ; Bendamustine; Cytarabine; Prednisone; Rituximab; Vincristine
Indications Mantle-cell lymphoma
Focus Therapeutic Use
Acronyms FIL_COLUMN

19 Aug 2024 Planned End Date changed from 1 Feb 2027 to 1 Apr 2029.
19 Aug 2024 Planned primary completion date changed from 1 Feb 2025 to 1 Apr 2026.
22 Apr 2022 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com